First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.

Lunze, K; Gilbert, N; Mebus, S; Miera, O; Fehske, W; Uhlemann, F; Mühler, E G; Ewert, P; Lange, P E; Berger, F; Schulze-Neick, I

Lunze, K; Gilbert, N; Mebus, S; Miera, O; Fehske, W; Uhlemann, F; Mühler, E G; Ewert, P; Lange, P E; Berger, F; Schulze-Neick, I.

Affiliation

Lunze K; Klinik für angeborene Herzfehler/Kinderkardiologie, Deutsches Herzzentrum Berlin, Berlin, Germany.

Eur J Clin Invest ; 36 Suppl 3: 32-8, 2006 Sep.

Article in En | MEDLINE | ID: mdl-16919008

Subject(s)

Antihypertensive Agents/administration & dosage; Hypertension, Pulmonary/drug therapy; Phosphodiesterase Inhibitors/administration & dosage; Piperazines/administration & dosage; Sulfonamides/administration & dosage; Administration, Oral; Adolescent; Adult; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Test/methods; Heart Defects, Congenital/complications; Heart Defects, Congenital/physiopathology; Humans; Hypertension, Pulmonary/complications; Hypertension, Pulmonary/physiopathology; Middle Aged; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Phosphodiesterase Inhibitors / Piperazines / Sulfonamides / Hypertension, Pulmonary / Antihypertensive Agents Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Humans / Middle aged Language: En Year: 2006 Type: Article

Search on Google

XML

PubMed Links